Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889 · View on ClinicalTrials.gov ↗
Study Summary
This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
Conditions Studied
Interventions
- BIOLOGICAL GB-0895 (SC)
- DRUG Placebo (SC)
Study Locations (13)
Other
- Charite Research Organization GmbH — Berlin
- IKF Pneumologie — Frankfurt
- Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM) — Hanover
- Hammersmith Medicines Research — London
- Queen Anne Street Medical Center — London
- Medicines Evaluation Unit (MEU) — Manchester
- Simbec-Orion Clinical Development — Merthyr Tydfil
Florida
- Alcanza — DeLand
- Miami Research Institute of South Florida — Miami
- Omega Research — Orlando
Minnesota
- Nucleus Network — Saint Paul
North Carolina
- Southeastern Research Center — Winston-Salem
Texas
- DM Clinical Research — Tomball
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07116889
The ClinicalTrials.gov registry entry for NCT07116889 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Generate Biomedicines, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions — of which GB-0895 (SC) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07116889 reports 13 study locations spanning 5 distinct geographic areas — top geographies include Other, Florida, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07116889 about?
NCT07116889 is a clinical study titled "A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD". This study is testing the safety, tolerability, pharmacokinetics and pharmacodynamics of GB-0895.
What is the current status of trial NCT07116889?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 156 participants. The study started on 2023-12-12. Estimated completion is 2027-05.
What conditions does trial NCT07116889 study?
This clinical trial studies the following conditions: Asthma, COPD (Chronic Obstructive Pulmonary Disease). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07116889?
The interventions under investigation include: GB-0895 (SC) (BIOLOGICAL), Placebo (SC) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07116889?
This trial is sponsored by Generate Biomedicines, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07116889 being conducted?
This trial has 13 study locations across Florida, Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.